Strategies to Improve Patient Access to Prescription Digital Therapeutics

Overview

Prescription Digital Therapeutics (PDTs) offer evidence-based treatments via FDA-cleared software but face limited patient access in the U.S. due to outdated reimbursement frameworks. Legislative efforts like the Access to Prescription Digital Therapeutics Act aim to modernize Medicare coverage, aligning reimbursement with clinical rigor and expanding access while reducing healthcare costs.

Background

PDTs represent a novel class of treatments delivered through software, classified as Class II Software as a Medical Device by the FDA. Since the first FDA-cleared prescription app in 2010, nearly twenty PDTs have been approved in the U.S., addressing conditions from mental health to stroke recovery. Despite their clinical benefits, current Medicare and broader U.S. reimbursement policies do not adequately support PDT coverage, limiting patient access. In contrast, countries like Germany have implemented national reimbursement programs that have facilitated widespread PDT adoption.

Data Highlights

Key Findings

• U.S. Medicare’s reimbursement framework, designed decades ago, lacks pathways for Software as a Medical Device, hindering PDT access.
• The Access to Prescription Digital Therapeutics Act (S.1702) proposes a dedicated Medicare benefit category to streamline PDT reimbursement.
• Germany’s DiGA program has enabled nearly 861,000 PDT app activations across 64 products from 2020 to 2024, demonstrating scalable access and cost-effectiveness.
• Early German implementation focused on low-risk devices, with some products withdrawn due to insufficient sustained efficacy evidence, highlighting the need for robust post-market data.
• Emerging PDTs increasingly integrate AI mechanisms, though reimbursement pathways for AI-driven PDTs remain undefined.
• Expanding reimbursement could bridge access gaps, especially for underserved populations, and align incentives to prevent payers from blocking cost-saving digital interventions.

Clinical Implications

Clinicians should be aware of the evolving policy landscape that may soon improve patient access to FDA-cleared PDTs through Medicare and other payers. Adoption of PDTs can enhance care delivery by providing on-demand, evidence-based digital interventions that complement traditional therapies. Monitoring legislative developments and reimbursement changes will be critical to integrating PDTs effectively into clinical practice.

Conclusion

Modernizing reimbursement policies to include Prescription Digital Therapeutics is essential to unlock their full potential in improving patient outcomes and reducing healthcare costs. Legislative initiatives like the Access to PDT Act represent pivotal steps toward aligning U.S. healthcare with global digital therapeutic advancements.

References

1. FDA 2010 -- First FDA-cleared prescription app for diabetes
2. German Federal Institute for Drugs and Medical Devices (BfArM) -- DiGA Program Data 2020-2024
3. Access to Prescription Digital Therapeutics Act (S.1702) -- 2022
4. Peterson Health Technology Institute -- Economic Review of Digital Mental Health Treatments